A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy

Single‐agent chemotherapy with dacarbazine continues to be the standard of care for the treatment of metastatic melanoma. However, there is a large population of patients who have failed first‐line therapy and might benefit from additional treatment. In the current study, the authors evaluated the antitumor effects and toxicity of vinorelbine therapy in patients who had failed one prior systemic therapy.

[1]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[2]  E. Krementz,et al.  Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A) , 1984, Cancer.

[3]  G. Mathé,et al.  Phase I pharmacologic study of a new Vinca alkaloid: navelbine. , 1985, Cancer letters.

[4]  J C Briggs,et al.  Cutaneous melanoma. , 1993, Journal of the American Academy of Dermatology.

[5]  H. Burris,et al.  Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. , 1994, Seminars in oncology.

[6]  E. Winer,et al.  Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Santoro,et al.  Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  R. Larsson,et al.  In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells. , 1996, Journal of experimental therapeutics & oncology.

[9]  S. Retsas,et al.  Taxol and vinorelbine: a new active combination for disseminated malignant melanoma , 1996, Anti-cancer drugs.

[10]  A. Photiou,et al.  In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. , 1997, European journal of cancer.

[11]  M. Del Vecchio,et al.  Preliminary Experience with High-Dose Cisplatin, Reduced Glutathione and Natural Interferon-α in Dacarbazine-Resistant Malignant Melanoma , 1998, Tumori.

[12]  Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group. , 1999, Melanoma research.

[13]  A. Harris,et al.  Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine , 2000, British Journal of Cancer.

[14]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma. , 2000, Cancer.

[16]  A. Buzaid,et al.  A Phase II study of “decrescendo” interleukin‐2 plus interferon‐α‐2a in patients with progressive metastatic melanoma after chemotherapy , 2000, Cancer.

[17]  H. Kittler,et al.  Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients , 2001, Melanoma research.

[18]  J. Lee,et al.  Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Haenssle,et al.  Inefficacy of vindesine monotherapy in advanced stage IV malignant melanoma patients previously treated with other chemotherapeutic agents , 2003, Melanoma research.

[20]  A. Hauschild,et al.  Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial , 2003, Melanoma research.

[21]  V. Sondak,et al.  Phase II Trial of CI-980 in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – A Southwest Oncology Group Study , 2004, Investigational New Drugs.

[22]  V. Sondak,et al.  A Phase II Trial of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – Southwest Oncology Group Study , 2002, Investigational New Drugs.

[23]  Robert N. Hughes,et al.  Cancer: Principles and Practice of Oncology , 2005 .

[24]  A. Photiou,et al.  Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines , 2005, Journal of Cancer Research and Clinical Oncology.